Genfit (NASDAQ:GNFT – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Profitability
This table compares Genfit and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genfit | N/A | N/A | N/A |
| Monte Rosa Therapeutics | N/A | -49.15% | -38.93% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Genfit and Monte Rosa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genfit | 0 | 0 | 2 | 0 | 3.00 |
| Monte Rosa Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Volatility and Risk
Genfit has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.
Insider & Institutional Ownership
8.8% of Genfit shares are owned by institutional investors. Comparatively, 80.1% of Monte Rosa Therapeutics shares are owned by institutional investors. 4.2% of Genfit shares are owned by insiders. Comparatively, 5.3% of Monte Rosa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Genfit and Monte Rosa Therapeutics’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genfit | $20.20 million | 9.82 | -$24.99 million | N/A | N/A |
| Monte Rosa Therapeutics | N/A | N/A | -$108.50 million | ($2.57) | -2.32 |
Genfit has higher revenue and earnings than Monte Rosa Therapeutics.
Summary
Genfit beats Monte Rosa Therapeutics on 6 of the 9 factors compared between the two stocks.
About Genfit
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops an orally bioavailable molecular glue degrader for GSPT1, a a translation termination factor for the treatment of Myc-driven cancers. It also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as gout and Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and a therapeutically-relevant protein in hemoglobinopathies. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
